



Major Career Roles

Chair, Roche Holding AG
Chair, Diageo
Chair, Neogene Therapeutics
Chair, HMNC Holding Brain Health GmbH
Independent Director, Allogene Therapeutics
Board of Directors, Emil Frey Holdings

Other Career Highlights

COO, Glaxo plc
Board member, Allianz SE
Vice Chair, Wisekey Intl Holding Ltd
Senior Independent Non-Executive Director, Aris Bioscience plc
Board of Directors, Citigroup Inc. New York
Independent Director, Kite Pharma Inc.
Director, Chugai Pharmaceutical Company Ltd
Independent Director, Zurich Insurance Group AG
Chair, INSEAD
Chair, Board of Directors, International Centre for Missing and Exploited Children
Adviser, Breakthrough Properties (US)

Dr Franz Humer has over 30 years of international experience serving as Chair across FTSE 100, SMI and STOXX Europe 50 companies, giving him a vast wealth of multi-industry knowledge of pharmaceutical and biotech, and private equity companies.

Franz was previously Chair of Roche Holding AG, Chair of Diageo and Neogene Therapeutics. He is currently Chair of HMNC Brain Health, Chair of the Board of Directors of the International Centre for Missing and Exploited Children, and Chair of the Humer Foundation and Chair of Kallyope Inc.

Professional experience from positions in the pharmaceuticals industry at, among others, Schering Plough Corp. and at Glaxo, where he was Managing Director of Glaxo Pharmaceuticals UK and a member of the Board of Glaxo Holdings plc. In 1995, he joined Hoffmann-La Roche as a member of its Board and the Head of its Pharmaceutical Division, progressing to become Chair and CEO in 2001, and between 2008 and 2014 the Chair of Roche Holding Ltd.

Franz was an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd (Japan), Aris Bioscience plc and Kite Pharma (biotech company in Los Angeles).

In addition to Franz's Chair roles he is currently a Board Director of Allogene Therapeutics and Emil Frey Holdings, and an Adviser to Temasek Holdings, Letterone Healthcare, Target PharmaSolutions and Breakthrough Properties, as well as a number of start-up companies.